Clinical Trial Continuity and the Impact of COVID-19
4 years ago
By Ben Parkes
Here’s a second chance to catch the fascinating keynote panel discussion lead by Josh Rose, VP GM Virtual Trial Solutions Business, IQVIA and joined by Eli Lilly and Co., EMD Serono/Merck KGaA and Janssen.
See how you can prepare for a post-Covid world and ensure your clinical trials are more patient-centric than ever before.
You can join IQVIA at our next Online Clinical Operations Strategy Meeting on November 16.
How to Reduce the Cost of Clinical Trial Supply Chain While Maintaining Quality and Efficiency
Clinical trial supply chain is a critical component of drug development, ensuring that drugs are available for testing, regulatory approval, and distribution. However, managing this supply chain can be challenging, with factors such as cost, quality, and efficiency all coming...
2 years agoHow to Reduce the Cost of Clinical Trial Supply Chain While Maintaining Quality and Efficiency
Clinical trial supply chain is a critical component of drug development, ensuring that drugs are available for testing, regulatory approval, and distribution. However, managing this supply chain can be challenging, with factors such as cost, quality, and efficiency all coming...
2 years ago
Raising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
3 years agoRaising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
3 years ago
Latest Advancements in Parkinson’s Treatment: CGT Shows Potential to Reverse Disease
Every hour, two more people are diagnosed with Parkinson’s in the UK and the global patient population continues to rise. To date, there are no disease-modifying therapies available on the market for Parkinson's (PD) patients. Pharmaceutical company Bayer is simultaneously...
3 years agoLatest Advancements in Parkinson’s Treatment: CGT Shows Potential to Reverse Disease
Every hour, two more people are diagnosed with Parkinson’s in the UK and the global patient population continues to rise. To date, there are no disease-modifying therapies available on the market for Parkinson's (PD) patients. Pharmaceutical company Bayer is simultaneously...
3 years ago